Molecule_ID,SMILES,Vina_Best_Affinity_kcal_mol,Vina_Second_Affinity_kcal_mol,Vina_Third_Affinity_kcal_mol,Predicted_IC50_nM,Predicted_pIC50,BindingForge_Score,Lipinski_Violations,QED_Score,SA_Score,Design_Strategy,Source,Original_ID,Dataset_Date,Status,Validation_Notes
NOVEL_02,n1c2c(ncnc2c(Nc2cccc(NC(C)C)c2)cc1)C1CCC1,-8.3,-8.0,-7.4,8.7,8.06,0.87,0,0.78,2.4,Quinazoline with cyclobutyl and isopropylamine,Combined_EGFR_Docking_Analysis,molecule_02,2025-07-30,Validated_Docking,"Good binding affinity, quinazoline scaffold"
NOVEL_03,c1ccc(cc2c1Nc1ncnc(c1)NCCCCC1)Nc1ncnc2C1CCOCC1,-8.4,-8.2,-7.7,6.8,8.17,0.89,0,0.82,2.6,Complex multi-ring system with morpholine - BEST BINDER,Combined_EGFR_Docking_Analysis,molecule_03,2025-07-30,Validated_Docking,"BEST PERFORMER: -8.4 kcal/mol, complex structure"
NOVEL_16,Cc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1,-8.1,-7.7,-7.5,12.4,7.91,0.85,0,0.79,2.3,"Methylated quinazoline with F,Cl substitution",Combined_EGFR_Docking_Analysis,molecule_16,2025-07-30,Validated_Docking,"Moderate binding, classical EGFR inhibitor pattern"
NOVEL_17,c1ccc(Nc2nccc(c3ccccc3)n2)cc1,-7.7,-7.5,-7.2,18.2,7.74,0.82,0,0.76,2.8,Biphenyl-pyrimidine scaffold,Combined_EGFR_Docking_Analysis,molecule_17,2025-07-30,Validated_Docking,"Lower binding, simpler biphenyl structure"
NOVEL_18,COc1ccc(Nc2nccc(c3ccccc3)n2)cc1,-7.9,-7.6,-7.0,15.1,7.82,0.84,0,0.81,2.5,Methoxy biphenyl-pyrimidine system,Combined_EGFR_Docking_Analysis,molecule_18,2025-07-30,Validated_Docking,"Decent binding, methoxy substitution"
